Shanghai/Hong Kong – – October 02, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) will present preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2026), running November 4-8 at the Phoenix Convention Center in Arizona.
Chief Scientific Officer to present CD2-based platform data on November 6
Dr. Bing Hou, Antengene's Chief Scientific Officer, will deliver the presentation titled "A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking," filed under Abstract 15749. The session, categorized as Rapid Oral - Basic 1, is scheduled for 12:30 PM to 1:30 PM Eastern Time on November 6, corresponding to 1:30 AM to 2:30 AM Beijing time on November 7.
Platform builds on Antengene's existing AnTenGager TCE 2.0 technology
The Cos-TCE approach combines a CD3γε/δε-targeting antibody with steric-hindrance-based CD3 masking, extending Antengene's proprietary AnTenGager platform, which uses a "2+1" bivalent binding format, steric hindrance masking, and tailored CD3 sequences with fast on/off kinetics designed to reduce cytokine release syndrome while improving efficacy.
Pipeline spans autoimmune disease, solid tumors and hematological malignancies
Antengene has secured 35 investigational new drug approvals across the U.S. and Asia and 10 new drug application approvals in Asia Pacific markets. Its TCE programs include ATG-201 (CD19 x CD3, partnered with UCB), ATG-106 (CDH6 x CD3, partnered with K2 Therapeutics), ATG-112 (ALPPL2 x CD3), ATG-110 (LY6G6D x CD3), ATG-021 (GPRC5D x CD3), ATG-102 (LILRB4 x CD3) and ATG-107 (FLT3 x CD3). The company's commercial asset XPOVIO (selinexor) is approved in 10 markets including Mainland China, Taiwan, Hong Kong, South Korea, Singapore and Australia, with national insurance coverage secured in five of those jurisdictions.